Sitemap > Breaking Research > Neurodegenerative & Neuroelectrophysiological Disorders
Displaying 501 - 550 of 2157 results
- Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury.
- Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists.
- Over-expression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice.
- Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation.
- The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia.
- DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2.
- AM-36 modulates the neutrophil inflammatory response and reduces breakdown of the blood brain barrier after endothelin-1 induced focal brain ischaemia.
- Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystonia.
- Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist.
- Activation of adenosine A3 receptors reduces ischemic brain injury in rodents.
- Inhibition of integrin alphavbeta3 reduces blood-brain barrier breakdown in focal ischemia in rats.
- M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
- Avoidance of Abeta[(25-35)] / (H(2)O(2)) -induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53.
- Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia.
- Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury.
- Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
- Role of potassium channels in Abeta(1-40)-activated apoptotic pathway in cultured cortical neurons.
- Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites.
- Safinamide: from molecular targets to a new anti-Parkinson drug.
- Posttraumatic cerebral infarction in patients with moderate or severe head trauma.
- Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.
- Isoquinoline-1,3,4-trione and its derivatives attenuate beta-amyloid-induced apoptosis of neuronal cells.
- Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors.
- Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
- Macrocyclic inhibitors of beta-secretase: functional activity in an animal model.
- Acylguanidines as small-molecule beta-secretase inhibitors.
- Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors.
- Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists.
- N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated gamma-secretase.
- Synthesis and characterization of styrylchromone derivatives as beta-amyloid imaging agents.
- Chemokine fractalkine/CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons.
- Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
- Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
- In vivo measurement of plaque burden in a mouse model of Alzheimer's disease.
- Natalizumab and progressive multifocal leucoencephalopathy.
- Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Abeta42 peptide.
- NO-cGMP signaling and regenerative medicine involving stem cells.
- Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke.
- Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
- Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane.
- A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson's disease models.
- Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain.
- Design of potent inhibitors of human beta-secretase. Part 1.
- Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
- The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicity.
- Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
- Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis.
- Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis.
- Design of potent inhibitors of human beta-secretase. Part 2.
- Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro.